(Q45662866)

English

The prolonged culture of human immunodeficiency virus type 1 in primary lymphocytes increases its sensitivity to neutralization by soluble CD4.

scientific article published in March 2004

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

The prolonged culture of human immunodeficiency virus type 1 in primary lymphocytes increases its sensitivity to neutralization by soluble CD4. (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

Steven M. Wolinsky

7

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

author name string

Pavel Pugach

1

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

Shawn E Kuhmann

2

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

Joann Taylor

3

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

Andre J Marozsan

4

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

Amy Snyder

5

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

Thomas Ketas

6

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

John P Moore

9

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

language of work or name

0 references

publication date

1 March 2004

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

321

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

8-22

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone

2 references

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

based on heuristic

inferred from DOI database lookup

Expression and Characterization of CD4-IgG2, a Novel Heterotetramer That Neutralizes Primary HIV Type 1 Isolates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

Neutralizing antibody response during human immunodeficiency virus type 1 infection: type and group specificity and viral escape

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

Resistance of primary isolates of human immunodeficiency virus type 1 to soluble CD4 is independent of CD4-rgp120 binding affinity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

Reversal of human immunodeficiency virus type 1 IIIB to a neutralization-resistant phenotype in an accidentally infected laboratory worker with a progressive clinical course

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

Multiple interactions across the surface of the gp120 core structure determine the global neutralization resistance phenotype of human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

Envelope proteins from clinical isolates of human immunodeficiency virus type 1 that are refractory to neutralization by soluble CD4 possess high affinity for the CD4 receptor

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

Antibodies, viruses and vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

Relation between humoral responses to HIV gag and env proteins at seroconversion and clinical outcome of HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

Cell surface receptors, virus entry and tropism of primate lentiviruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

Genetic variation in AIDS viruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

Change in coreceptor use correlates with disease progression in HIV-1--infected individuals

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

Antibody and HIV-1 gp120 recognition of CD4 undermines the concept of mimicry between antibodies and receptors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

Chemokine receptor regulation and HIV type 1 tropism in monocyte-macrophages

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

Beyond receptor expression: the influence of receptor conformation, density, and affinity in HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

Envelope glycoprotein determinants of increased fusogenicity in a pathogenic simian-human immunodeficiency virus (SHIV-KB9) passaged in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

Interactions of polyclonal and monoclonal anti-glycoprotein 120 antibodies with oligomeric glycoprotein 120-glycoprotein 41 complexes of a primary HIV type 1 isolate: relationship to neutralization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

Novel anti-CD4 monoclonal antibodies separate human immunodeficiency virus infection and fusion of CD4+ cells from virus binding

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

Nonneutralizing antibodies to the CD4-binding site on the gp120 subunit of human immunodeficiency virus type 1 do not interfere with the activity of a neutralizing antibody against the same site

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

Molecular evolution of human immunodeficiency virus env in humans and monkeys: similar patterns occur during natural disease progression or rapid virus passage

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

Cell-surface heparan sulfate facilitates human immunodeficiency virus Type 1 entry into some cell lines but not primary lymphocytes.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

Macrophage are the principal reservoir and sustain high virus loads in rhesus macaques after the depletion of CD4+ T cells by a highly pathogenic simian immunodeficiency virus/HIV type 1 chimera (SHIV): Implications for HIV-1 infections of humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

Viral persistence: HIV's strategies of immune system evasion

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

A replication-competent, neutralization-sensitive variant of simian immunodeficiency virus lacking 100 amino acids of envelope

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

Importance of B-cell responses for immunological control of variant strains of simian immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

Entry Inhibitors SCH-C, RANTES, and T-20 Block HIV Type 1 Replication in Multiple Cell Types

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

Novel therapies based on mechanisms of HIV-1 cell entry.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

Emerging cytopathic and antigenic simian immunodeficiency virus variants influence AIDS progression.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

CC-chemokines enhance the replication of T-tropic strains of HIV-1 in CD4(+) T cells: role of signal transduction

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

Soluble CD4 and CD4 immunoglobulin-selected HIV-1 variants: a phenotypic characterization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

Increased In Vitro Cytopathicity of CC Chemokine Receptor 5–Restricted Human Immunodeficiency Virus Type 1 Primary Isolates Correlates with a Progressive Clinical Course of Infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocyte-derived macrophages

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

Surface CD4 Is Critical to in Vitro HIV Infection of Human Alveolar Macrophages

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

The entry of entry inhibitors: a fusion of science and medicine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

New targets for inhibitors of HIV-1 replication

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

Adaptation of two primary human immunodeficiency virus type 1 isolates to growth in transformed T cell lines correlates with alterations in the responses of their envelope glycoproteins to soluble CD4.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

The CCR5 and CXCR4 coreceptors--central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

The V1/V2 region of human immunodeficiency virus type 1 modulates the sensitivity to neutralization by soluble CD4 and cellular tropism

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

Human immunodeficiency virus type 2 envelope glycoprotein: differential CD4 interactions of soluble gp120 versus the assembled envelope complex.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

Host cell glycosylation of viral glycoproteins--a battlefield for host defence and viral resistance

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

A global neutralization resistance phenotype of human immunodeficiency virus type 1 is determined by distinct mechanisms mediating enhanced infectivity and conformational change of the envelope complex

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

Cell-surface heparan sulfate proteoglycan mediates HIV-1 infection of T-cell lines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

Critical role of enhanced CD4 affinity in laboratory adaptation of human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

Evaluation of current approaches to inhibit HIV entry.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

gp120: Biologic aspects of structural features

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

Human immunodeficiency virus type 1 primary isolate neutralization resistance is associated with the syncytium-inducing phenotype and lower CD4 cell counts in subtype CRF01_AE-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

A role for carbohydrates in immune evasion in AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

Generation of a neutralization-resistant variant of HIV-1 is due to selection for a point mutation in the envelope gene.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

Rapid evolution of the neutralizing antibody response to HIV type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

Structural analysis of the human immunodeficiency virus-binding domain of CD4. Epitope mapping with site-directed mutants and anti-idiotypes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

Inhibiting sexual transmission of HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

Envelope glycoprotein determinants of neutralization resistance in a simian-human immunodeficiency virus (SHIV-HXBc2P 3.2) derived by passage in monkeys

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

Antibody-mediated neutralization of primary human immunodeficiency virus type 1 isolates: investigation of the mechanism of inhibition

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

Effect of major deletions in the V1 and V2 loops of a macrophage-tropic HIV type 1 isolate on viral envelope structure, cell entry, and replication

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

Molecular basis for cell tropism of CXCR4-dependent human immunodeficiency virus type 1 isolates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

Resistance of primary isolates of human immunodeficiency virus type 1 to neutralization by soluble CD4 is not due to lower affinity with the viral envelope glycoprotein gp120

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

Inhibition of virus attachment to CD4+ target cells is a major mechanism of T cell line-adapted HIV-1 neutralization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

Antibody neutralization and escape by HIV-1

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

The antigenic structure of the HIV gp120 envelope glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

Association of structural changes in the V2 and V3 loops of the gp120 envelope glycoprotein with acquisition of neutralization resistance in a simian-human immunodeficiency virus passaged in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

Continued utilization of CCR5 coreceptor by a newly derived T-cell line-adapted isolate of human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

Serum neutralization of feline immunodeficiency virus is markedly dependent on passage history of the virus and host system.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

based on heuristic

inferred from DOI database lookup

Selection for neutralization resistance of the simian/human immunodeficiency virus SHIVSF33A variant in vivo by virtue of sequence changes in the extracellular envelope glycoprotein that modify N-linked glycosylation.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

based on heuristic

inferred from DOI database lookup

Increased viral burden and cytopathicity correlate temporally with CD4+ T-lymphocyte decline and clinical progression in human immunodeficiency virus type 1-infected individuals.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

based on heuristic

inferred from DOI database lookup

Quantitative model of antibody- and soluble CD4-mediated neutralization of primary isolates and T-cell line-adapted strains of human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

based on heuristic

inferred from DOI database lookup

Human immunodeficiency virus type 1 mutants that escape neutralization by human monoclonal antibody IgG1b12. off.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

based on heuristic

inferred from DOI database lookup

Neutralizing antibodies in sera from macaques infected with chimeric simian-human immunodeficiency virus containing the envelope glycoproteins of either a laboratory-adapted variant or a primary isolate of human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

based on heuristic

inferred from DOI database lookup

Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

based on heuristic

inferred from DOI database lookup

Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

based on heuristic

inferred from DOI database lookup

Genetic subtype-independent inhibition of human immunodeficiency virus type 1 replication by CC and CXC chemokines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

based on heuristic

inferred from DOI database lookup

Expression of CCR5 increases during monocyte differentiation and directly mediates macrophage susceptibility to infection by human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

based on heuristic

inferred from DOI database lookup

Increase in soluble CD4 binding to and CD4-induced dissociation of gp120 from virions correlates with infectivity of human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

based on heuristic

inferred from DOI database lookup

Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2003.12.012

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VIROL.2003.12.012

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45662866&oldid=1477697851"